Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021
Minerva Neurosciences (NASDAQ: NERV) will release its financial results for the first quarter of 2021 on May 12, 2021. The company will host a conference call at 8:30 a.m. Eastern Time to discuss these results. Interested parties can access the call by dialing (877) 312-5845 domestically or (765) 507-2618 internationally, using conference ID 8981662. The call will also be available via live webcast on the company’s website, where an archived recording will be accessible for 30 days post-event.
- Minerva will disclose first-quarter financial results, providing investors with insights into company performance.
- None.
Management to host conference call
WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2021 on Wednesday, May 12, 2021. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 (domestic) or (765) 507-2618 (international) and referring to conference ID number 8981662. A live webcast of the conference call will be available online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 30 days.
The live webcast can be accessed under “Events and Presentations” in the Investors and Media section of Minerva’s website at ir.minervaneurosciences.com. The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences
Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
FAQ
When will Minerva Neurosciences release its Q1 2021 financial results?
What time is the conference call for Minerva's financial results?
How can I access the Minerva Neurosciences conference call?
Where can I find the archived webcast of Minerva's conference call?
What is the stock symbol for Minerva Neurosciences?
